Navigation Links
HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
Date:3/7/2012

An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). Scientists at Emory University and GeoVax Labs, Inc. developed a vaccine that has protected nonhuman primates against multiple exposures to simian immunodeficiency virus (SIV) given in three clusters over more than three years. SIV is the nonhuman primate version of HIV.

Harriet L. Robinson, PhD, chief scientific officer at GeoVax Labs, Inc., and former director of the division of microbiology and immunology at Yerkes National Primate Research Center, has been leading the research team with Rama Rao Amara, PhD, associate professor of microbiology and immunology, Yerkes National Primate Research Center and the Emory Vaccine Center.

The research was presented Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

The vaccine regimen included a DNA prime vaccine that co-expressed HIV proteins and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a normal protein that promotes the initiation of immune responses and thus enhances the ability of the vaccine to elicit blocking antibodies for the SIV virus before it enters cells.

Vaccination consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. The booster vaccine was MVA, an attenuated poxvirus expressing HIV proteins. Six months after the last vaccination, both vaccinated and unvaccinated animals were exposed to SIV through 12 weekly exposures, resulting in an 87 percent per exposure efficacy and 70 percent overall protection. Over the next two years uninfected animals were exposed multiple times in two more series, resulting in an 82 percent per exposure efficacy during the second series and an 84 percent per exposure efficacy during the third series.


'/>"/>
Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Headaches May Plague Many With HIV/AIDS
2. Children with HIV/AIDS falling through the cracks of treatment scale-up efforts
3. Despite Advances, HIV/AIDS Still Takes Heavy Emotional Toll
4. Advocates Push for Greater Awareness of HIV/AIDS
5. Preventing HIV/AIDS 1 SMS at a time
6. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
7. Boston Medical Center awarded $1M to expand HIV/AIDS patient care services
8. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
9. International AIDS Society urges world leaders at UN General Assembly High-Level Meeting on HIV/AIDS to integrate a fourth pillar -- HIV cure research -- into the global response to the epidemic
10. Key goals for building on 30 years of HIV/AIDS research
11. Preventing the spread of HIV/AIDS with humanized BLT mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... GI for Life announced today, that ... prices of their popular nutritional supplements: ColoVite Colon ... Discounts of 40% will be offered for a ... proprietary ColoVite supplement is a scientifically formulated vitamin supplement ... One easy-to-take colon vitamin with ALL the nutrients associated ...
(Date:11/26/2014)... 2014 Call 866-997-4948 (Us-Canada Toll Free) ... the details on sales(at)researchmoz(dot)us , Researchmoz.us announces a ... market 2014" with deep study of the report on ... high blood sugar. The global glucose monitoring market has ... growing number of diabetics in the world. Their numbers ...
(Date:11/26/2014)... 26, 2014 News Facts , ... capabilities at RSNA 2014 in Chicago. The company ... share diagnostic images, photos, videos and documents found ... #8107 will learn more about these innovative medical ... and partner initiatives – that enable more informed ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Parents need ... from sports concussions, an expert warns. Parents must ... and undergo standard, Dr. David Dodick, chair of the ... the Mayo Clinic College of Medicine in Scottsdale, Ariz. ... news release. Any coach involved with teens ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... of serious complications drop with intensive therapy, study shows ... controlling blood sugar levels and taking medications that lower ... can significantly reduce their risk of developing the most ... , In a study appearing in the July 27 ...
... , , , , ... DCTH ), a medical technology company developing a minimally invasive drug delivery platform ... the Company,s recent progress. In addition, the Company reported its financial results ... Recent Highlights , , , ...
... , , , ARLINGTON, ... today responded to the article in Pediatrics: ... L. Waag, S. Loff, Use of Di(2-Ethylhexyl)Phthalate-Containing Infusion Systems Increases the Risk ... Total parenteral nutrition - delivery of nutrition intravenously via ...
... , , ATLANTA, ... related to the diagnosis and treatment of infertility with ovulation induction ... emotional, scientific and financial aspects. Discussions include information about age related ... donor sperm or donor eggs. , , ...
... , , , ... California Cardiothoracic Surgery Center specializes in cardiothoracic surgery ... not seem like serious symptoms. In fact, most people brush off ... simple symptoms can be indications of the need for ...
... , DENVER, July 27 ... Blue Shield have come together to offer Chamber members a health ... access to both traditional and alternative medical care. Whether members choose ... more traditional treatment regimens, the Chamber Plan,s BlueFreedom accommodates their healing ...
Cached Medicine News:Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Delcath Systems Provides Update on Progress 2Health News:Delcath Systems Provides Update on Progress 3Health News:Delcath Systems Provides Update on Progress 4Health News:Delcath Systems Provides Update on Progress 5Health News:Delcath Systems Provides Update on Progress 6Health News:Delcath Systems Provides Update on Progress 7Health News:ACC Responds to Study Published in Pediatrics About Phthalate and IV Tubing 2Health News:Southern California Surgical Center (heart411.com) Specializes in Mitral Valve Replacement 2Health News:Anthem Blue Cross and Blue Shield Introduces a Health Insurance Solution With a Special 'Boulder Flair' to Chamber Members 2
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... 2014 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... in New York on Wednesday, December ... Dr. Helen Torley , President and Chief Executive Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:11/24/2014)... , Nov. 24, 2014  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today that ... Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at ... City . A live webcast of the ... and will feature an overview of the company by ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3
... 2012   AMRI (NASDAQ: AMRI ), ... today the appointment of Ian Shott as President of ... and CEO. In this newly created role, Mr. Shott ... including the company,s site in Wales, United Kingdom, and ...
... 2012  Dr. Barry Edison announces that Barry Edison ... has the Pelleve® Wrinkle Reduction System, a revolutionary ... Dr. Edison uses Pelleve—an advanced radiofrequency technology—because the ... with noticeable results. "I am proud to now ...
Cached Medicine Technology:AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment 2